Yamashita Y, Morimoto T, Muraoka N, Shioyama W, et al. Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial). Circulation 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072758.
PMID: 39556015